Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptorum Group Ltd APM

Healthcare Biotechnology
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which... see more

Recent & Breaking News (NDAQ:APM)

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Business Wire December 22, 2022

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Business Wire December 16, 2022

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Business Wire December 9, 2022

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire November 25, 2022

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Business Wire November 25, 2022

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Business Wire November 18, 2022

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Business Wire November 8, 2022

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Business Wire September 30, 2022

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire September 23, 2022

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Business Wire September 15, 2022

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Business Wire September 15, 2022

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

Business Wire August 25, 2022

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire August 19, 2022

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 - 26 2022

Business Wire May 17, 2022

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Business Wire May 2, 2022

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

Business Wire April 29, 2022

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Business Wire April 25, 2022

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Business Wire April 22, 2022

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Business Wire January 20, 2022

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Business Wire January 18, 2022